In a Phase 2a study, ABBV-466 achieved higher endoscopic remission rates in patients with Crohn's disease than either anti-IL-23 p19 or anti-α4β7 monotherapy at Week 12, the primary ...
New and updated data across seven assets in lung, colorectal, ovarian, prostate and gastric cancers underscore the potential of AbbVie's oncology portfolio to address diverse patient needs ...
AbbVie's leadership in Inflammatory Bowel Disease (IBD) research programs Latest long-term and real-world data with ...
Higher rates of endoscopic remission and ulcer-free endoscopy were observed following subcutaneous SKYRIZI® (risankizumab-rzaa)treatment versus placeboi Results build on previously reported ...
New Phase 3 AFFIRM data show higher rates of clinical and endoscopic response in Crohn's disease patients treated with subcutaneous SKYRIZI versus placebo across all efficacy endpoints ...
NORTH CHICAGO, Ill., Oct. 7, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted two Breakthrough Therapy Designations (BTDs) for ...
NORTH CHICAGO, Ill. and COPENHAGEN, Denmark, Oct. 5, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) today announced positive topline results from the Phase 3 EPCORE DLBCL-2 ...
As a highly focused research-driven biopharmaceutical company, AbbVie takes on the toughest health challenges. But we do more than treat diseases - we aim to make a remarkable impact on people's lives ...
The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on AbbVie's website for historical purposes only. AbbVie assumes no ...
For further information: Media: Gabby Tarbert, (224) 244-0111; Investors: Liz Shea, (847) 935-2211; Todd Bosse, (847) 936-1182; Jeffrey Byrne, (847) 938-2923 The information in the press releases on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results